Every Form 4 that Ibio (IBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBIO filings page.
iBio, Inc. reported that its Chief Medical Officer, Molly Carr, received a grant of stock options covering 430,000 shares of common stock. The options have an exercise price of $1.40 per share and expire on July 30, 2036, with all 430,000 options held directly after the grant.
The award was granted on July 31, 2026 as an inducement award outside the iBio, Inc. 2023 Omnibus Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest 25% on the one-year anniversary of the grant date, with an additional 6.25% vesting every three months thereafter, contingent on Ms. Carr’s continued employment.
iBio, Inc. director Elizabeth Stoner received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of 1.42 per share and expire on 2036-05-17. They vest monthly on a pro rata basis over 36 months, and following this award she holds 60,000 options in total.
iBio, Inc. insider activity: Chief Legal Officer Banjak Marc reported open-market purchases of iBio common stock. On March 26, 2026, he bought 12,500 shares at $1.6425 per share and another 1,434 shares at $1.76 per share.
After these two purchases, his directly held position increased to 25,000 shares of iBio common stock, with no sales or derivative transactions reported in this filing.
iBio, Inc.’s Chief Financial Officer Felipe Duran purchased 24,835 shares of common stock in the open market. The transactions occurred on March 19, 2026 at prices ranging from $2.01 to $2.02 per share, with a weighted average purchase price of $2.0186.
Following these purchases, Duran directly owns 35,974 shares of iBio common stock. The filing notes that the shares were acquired through multiple trades within the price range, and the CFO has committed to provide detailed trade breakdowns upon request.
iBio, Inc. director and officer Martin Brenner bought 12,336 shares of common stock in an open-market transaction at $2.02 per share. This was a direct purchase, classified as a routine open-market buy.
Following this transaction, Brenner directly owns 30,652 shares of iBio common stock.
iBio, Inc. reported that its Chief Legal Officer, Marc Banjak, received a grant of stock options on January 28, 2026. The award covers 146,000 stock options with an exercise price of $2.23 per share, all held directly.
According to the vesting terms, 25% of the common stock underlying these options will vest on the one-year anniversary of the grant date. The remaining options will then vest in equal quarterly installments over the following 36 months, so long as Banjak remains employed by iBio.
iBio, Inc. reported that its Chief Financial Officer, Felipe Duran, received a grant of stock options covering 179,000 shares of common stock on January 28, 2026 at an exercise price of $2.23 per share. All 179,000 options were reported as directly owned after the grant.
The options vest over time. 25% of the underlying shares will vest on the one-year anniversary of the grant date, and the remaining options will vest in equal quarterly installments over the following 36 months, as long as Duran remains employed by iBio. The options become exercisable starting January 28, 2027 and are scheduled to expire on January 27, 2036.
iBio, Inc. reported that its Chief Executive Officer and Chief Scientific Officer, Martin Brenner, who also serves as a director, received a grant of stock options. On January 28, 2026, he was awarded 479,000 stock options to purchase common stock at an exercise price of $2.23 per share.
According to the filing, 25% of the underlying shares will vest on the one-year anniversary of the grant date. The remaining 75% will vest in equal quarterly installments over the following 36 months, as long as Brenner remains employed by iBio. After this grant, he beneficially owns 479,000 stock options directly.
iBio, Inc. reported a stock option grant to a director on a Form 4. On 11/20/2025, the director received 13,500 stock options with an exercise price of $1 per share, expiring on 11/19/2035. These options vest pro rata on a monthly basis over twelve months starting on the grant date. Following this transaction, the director beneficially owns 13,500 derivative securities, held as a direct ownership position.
iBio, Inc. (IBIO) reported a routine insider equity grant on a Form 4. A company director received a stock option (right to buy) covering 13,500 shares of common stock on 11/20/2025 with an exercise price of $1 per share. The option expires on 11/19/2035, giving a long window to purchase shares at that price. These options vest on a pro rata monthly basis over twelve months starting from the grant date, meaning the director earns the right to exercise a portion of the option each month during the first year.
iBio, Inc. (IBIO) reported a director equity award on a Form 4. On 11/20/2025, the reporting person received a stock option grant covering 13,500 shares of iBio common stock. The options have an exercise price of $1 per share and an expiration date of 11/19/2035.
The filing states that these options vest on a pro rata basis each month over twelve months, starting on the grant date. Following this grant, the reporting person beneficially owns 13,500 derivative securities directly in the form of these options.
iBio, Inc. (IBIO) disclosed that a director received a new stock option grant reported on Form 4. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1 per share. These options vest on a pro rata monthly basis over twelve months starting from the grant date, aligning the director’s compensation with the company’s share performance over the coming year. The options have an expiration date of 11/19/2035 and are held as direct ownership by the reporting person.
iBio, Inc. (IBIO) reported that one of its directors received a new stock option grant. On 11/20/2025, the director was granted options to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share.
These options vest pro rata on a monthly basis over twelve months starting from the grant date, meaning the director earns a portion of the options each month during the first year. The options have an expiration date of 11/19/2035, giving a long period in which they may be exercised, subject to the vesting schedule and any applicable company or regulatory requirements.
iBio, Inc. reported a stock-based compensation grant to one of its directors. On 11/20/2025, the director received a stock option to purchase 13,500 shares of iBio common stock at an exercise price of $1.00 per share. The option becomes exercisable gradually, vesting in equal monthly installments over twelve months starting on the grant date, and expires on 11/19/2035 if not exercised. The filing indicates the director holds these options directly.
iBio (IBIO) reported an insider equity grant: its Chief Financial Officer received 75,000 stock options at an exercise price of $0.893 on 10/20/2025. The options are exercisable starting 10/20/2026 and expire on 10/19/2035.
Vesting is 25% on the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over 36 months, contingent on continued employment. Following the grant, the officer beneficially owned 75,000 derivative securities, held directly.
iBio, Inc. (IBIO) reported an insider equity grant to its Chief Legal Officer. On 10/20/2025, the officer received a stock option to purchase 55,000 shares of common stock at an exercise price of $0.893 per share.
The option vests with 25% on the one-year anniversary of the grant, then the remainder in equal quarterly installments over 36 months, contingent on continued employment. The option becomes exercisable beginning 10/20/2026 and expires on 10/19/2035. The filing lists ownership of these derivative securities as Direct.
iBio, Inc. (IBIO) reported an insider equity award. Martin Brenner was granted 180,000 stock options at an exercise price of $0.893 on 10/20/2025.
The options vest 25% on 10/20/2026, with the remainder vesting in equal quarterly installments over 36 months, and they expire on 10/19/2035. Following the grant, 180,000 derivative securities are beneficially owned directly. Brenner is the company’s Chief Executive Officer, Chief Scientific Officer, and a Director. The transaction was coded A (grant) on Form 4.